CD274 and head and neck squamous cell carcinoma: This finding led to the recommendation of pembrolizumab monotherapy as first-line treatment in patients with recurrent unresectable and/or metastatic HNSCC with CPS ≥1 and the recommendation of pembrolizumab combined with platinum and 5-fluorouracil-based chemotherapy for patients with negative PD-L1 measured by CPS.